Clinart, Inc. has been acquired by Clinical Trial & Consulting (CTI)Washington, DC, (August 31, 2020)FOCUS Investment Banking (“FOCUS”), a Washington DC-based investment bank, represented Clinart, a regional CRO (Contract Research Organization) located in Dubai, in its acquisition by CTI, Clinical Trial and Consulting Services, an international CRO headquartered in Cincinnati, Ohio.

CTI helps companies develop drugs and medical devices and assists them in obtaining regulatory approval. The acquisition of Clinart will expand CTI’s total footprint to more than 60 countries, spanning six continents. Clinart’s staff increases CTI’s overall headcount to 900 employees worldwide.

The deal closed in late August, 2020. Terms of the transaction were not disclosed. Founded in 2008, Clinart is a full-service CRO located in Dubai with offices throughout the Middle East. The company serves the pharmaceutical and health care industries.

“We are excited to welcome Clinart to the CTI team and we look forward to further growth in partnership with Clinart,” said Dr. Tim Schroeder, CEO of CTI. “This acquisition has been in the works for quite some time, and despite the global crises we’re currently experiencing, we felt passionately about moving this deal forward for the future success of our organization. In fact, this merger will allow both companies to continue to expand the global reach of their important work in COVID-19 research.”

“This transaction now places CTI in an area of the world with many strategic advantages such as ready access to human populations with unique genetic makeups,” said James Hawkins, PhD, Managing Director at FOCUS. Added Evans Love, Principal at FOCUS: “Clinart extends CTI’s reach, adding access and expertise expected to benefit both organizations moving forward.”

Clinart CEO, Dr. Alaa Assem, will join CTI as its Managing Director of the Middle East and Northern Africa region. “Now that Clinart has reached a critical growth milestone in the Middle East, we couldn’t want for a better acquisition partner than an international player like CTI. We are excited about future growth prospects,” he said.

*These testimonials may not be representative of the experience of all clients; testimonials are not a guarantee of future performance or success.

About FOCUS Investment Banking

With more than three decades of experience, FOCUS Investment Banking is a trusted name in middle market M&A advisory services worldwide. Whether helping to sell, buy, or raise capital, FOCUS strives to maximize the value of every transaction to the benefit of its clients. Securities transactions conducted by FOCUS Securities LLC, an affiliated company, registered Broker Dealer member FINRA/SIPC. For more information, visit

PDF Available for DownloadDownload this press release as a PDF

Kahla Cooper is the Director of Marketing at FOCUS. In this role, Ms. Cooper designs and implements the overall marketing strategy. Ms. Cooper works with each industry team leader to define programs in order to promote and brand FOCUS’ suite of capabilities.